Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites

By P. Angeli, P. Ginés, F. Wong, M. Bernardi, T. Boyer, A. Gerbes, Richard Moreau, R. Jalan, S. Sarin, S. Piano and 8 more. Gut, 2015

1,172 citations recorded by the source corpus.

Acute renal failure (ARF) is a common complication in patients with decompensated cirrhosis. The traditional diagnostic criteria of renal failure in these patients were proposed in 19961 and have been refined in subsequent years.2 According to these criteria, ARF is defined as an increase in serum creatinine (sCr) of ≥50% from baseline to a final value >1.5 mg/dL (133 µmol/L). However, the threshold value of 1.5 mg/dL (133 µmol/L) sCr to define renal failure in patients with decompensated cirrhosis has been challenged.3 ,4 In addition, the timeframe to distinguish acute from chronic renal failure has not been clearly identified, the only exception being type 1 hepatorenal syndrome (HRS). Meanwhile, new definitions for ARF, now termed acute kidney injury (AKI), have been proposed and validated in patients without cirrhosis.5–7 Recently these new criteria were also proposed and applied in the diagnosis of AKI in patients with cirrhosis.3 ,8–15 Thus, in December 2012, the International Club of Ascites (ICA) organised a consensus development meeting in Venice, Italy, in order to reach a new definition of AKI in patients with cirrhosis. The discussion among the experts continued thereafter for 2 years, both online and through several meetings, between those experts who had different positions on crucial points on the subject. This paper reports the scientific evidence supporting the final proposal of a new approach to the diagnosis and treatment of this condition, on which the experts agreed. AKI is defined as an acute significant reduction in the glomerular filtration rate (GFR). sCr remains the most practical biomarker of renal function in patients with ARF (with or without cirrhosis). However, sCr as a biomarker of renal function has many limitations in clinical practice since it is influenced by bodyweight, race, age, and gender. The use of sCr in patients with cirrhosis is …

Subfields: Hepatology, Nephrology, Pharmacology

View Paper: https://www.semanticscholar.org/paper/9cb5163bd16ab3ed9478d53dcd4b025be49b6ed5

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Hepatology

In Nephrology

Citations in the corpus

Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension. (2015, background): “16 − Hyponatremia (<130 mEq/L) − Acute kidney injury [17] • [This assumes that drugs that could precipitate these events (e.”
Diagnosis, Evaluation, and Management of Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases (2021, methodology): “Differentiating ATN from the severe form of HRS-AKI is particularly challenging because of the lack of clear diagnostic indicators (15, 215, 218-220, 223, 224).”
EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. (2018, background): “These criteria were not considered by the recent International Club of Ascites (ICA) consensus because (a) these patients are frequently oliguric with avid sodium retention, despite a relatively normal GFR, (b) they may have an increased urine output because of diuretics, and (c) on a regular ward, ”